Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 01, 2017 14:42 ET | Source: Melinta Therapeutics

Melinta Therapeutics Presenting In Vivo and In Vitro Results from Baxdela Studies at ASM Microbe

New Haven, Conn, June 01, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that five...
April 19, 2017 14:42 ET | Source: Melinta Therapeutics

Melinta Therapeutics Highlighting Activity of Baxdela as well as Progress on Macrolide and Pyrrolocytosine Candidates at ECCMID 2017

New Haven, Conn, April 19, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that there will...
May 19, 2015 16:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Study Demonstrates Significant Burden of Obesity on Patients' Recovery from Acute Bacterial Skin Infections

New Haven, CT, May 19, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today presented data that show the negative impact of obesity on patients' recovery from acute bacterial skin and skin structure...
February 09, 2015 08:00 ET | Source: Melinta Therapeutics

Melinta Therapeutics Secures up to $30 Million from Hercules Technology Growth Capital

New Haven, Conn, Feb. 9, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics announced today that it has entered into a $30 million growth capital debt financing agreement with Hercules Technology Growth...
January 08, 2015 15:08 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Eurofarma Laboratorios Enter into Commercialization and Distribution Agreements for Delafloxacin in Brazil

NEW HAVEN, Conn. and Sao Paolo, Brazil, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Eurofarma Laboratórios, one of the largest pharmaceutical companies in Brazil, announced that...
January 07, 2015 13:40 ET | Source: Melinta Therapeutics

Melinta Therapeutics' Lead Candidate Delafloxacin Yields Positive Top-Line Results in Phase 3 Study in Patients with ABSSSI

New Haven, Conn, Jan. 7, 2015 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced positive top-line results from the first of two Phase 3 PROCEED studies (study RX-3341-302, NCT01811732) to...
September 08, 2014 15:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today provided an update on the Company's innovative ESKAPE Pathogen Program. The ESKAPE Pathogen Program leverages Melinta's...